Targeting HER2 in breast cancer: overview of long-term experience
about
Immuno nanoparticles integrated electrical control of targeted cancer cell development using whole cell bioelectronic device.The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors.The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines
P2860
Targeting HER2 in breast cancer: overview of long-term experience
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting HER2 in breast cancer: overview of long-term experience
@ast
Targeting HER2 in breast cancer: overview of long-term experience
@en
Targeting HER2 in breast cancer: overview of long-term experience
@nl
type
label
Targeting HER2 in breast cancer: overview of long-term experience
@ast
Targeting HER2 in breast cancer: overview of long-term experience
@en
Targeting HER2 in breast cancer: overview of long-term experience
@nl
prefLabel
Targeting HER2 in breast cancer: overview of long-term experience
@ast
Targeting HER2 in breast cancer: overview of long-term experience
@en
Targeting HER2 in breast cancer: overview of long-term experience
@nl
P2093
P2860
P356
P1476
Targeting HER2 in breast cancer: overview of long-term experience
@en
P2093
Evan Lantz
Gerald M Higa
Ivan Cunningham
P2860
P304
P356
10.2147/IJWH.S5647
P407
P577
2010-08-09T00:00:00Z